Mutations in dihydropteroate synthase gene identified in some isolates
Clinical significance of resistance mutations remains under investigation
TMP-SMX still first-line; no validated clinical resistance threshold
Rationale for adjunctive corticosteroids
Class I recommendation based on multiple RCTs and meta-analyses
Reduces mortality and need for mechanical ventilation in moderate-to-severe PCP
Must be started within 72 hours of antimicrobial therapy initiation
Benefit in non-HIV patients less clearly established but extrapolated
Beta-D-glucan as therapeutic monitoring tool
Declining beta-D-glucan levels correlate with treatment response
Persistent elevation may indicate treatment failure
Serial monitoring every 5–7 days in severe cases
Treatment failure considerations
If no improvement after 5–7 days of TMP-SMX
Switch to IV pentamidine as salvage therapy
Pursue definitive BAL diagnosis if not yet obtained
Consider clindamycin-primaquine as alternative salvage regimen
Co-pathogens common in non-HIV patients
CMV, bacterial superinfection; metagenomic NGS may identify co-pathogens
Patient Discharge Instructions
copy discharge instructions
Discharge instructions for Pneumocystis jirovecii Pneumonia (PCP)
You have been treated for PCP, a serious lung infection that occurs when the immune system is weakened
It is critical that you take all of your antibiotic medication as prescribed for the full 21 days
Medication instructions
Take TMP-SMX (trimethoprim-sulfamethoxazole) at the prescribed dose with a full glass of water
Take atovaquone with food if prescribed — absorption is much better with a fatty meal
Do not stop any medications without talking to your doctor first
Prevention medication after discharge
You will need to take a daily antibiotic to prevent PCP from coming back
This preventive medication must be continued until your immune system has recovered
Activity and recovery
Rest and gradually increase activity as tolerated
Avoid contact with people who are sick while your immune system is recovering
Maintain good nutrition and hydration to support recovery
Follow-up appointments
Return to clinic within 1 week of discharge
Repeat blood tests will be needed to monitor your immune system and medication levels
If HIV was newly diagnosed, an HIV specialist appointment has been arranged
Return to the emergency department immediately for
Worsening shortness of breath or difficulty breathing at rest
New or worsening chest pain, especially sharp pain that worsens with breathing
Fever that is not improving after 5–7 days of treatment
Skin rash, especially blisters or mouth sores (possible drug reaction)
Yellowing of skin or eyes, dark urine, or easy bruising (liver or blood problems)
Swelling in legs or face, or decreased urine output (kidney problems)
Confusion, severe headache, or new neurological symptoms
Sudden onset severe chest pain or sharp pleurisy (pneumothorax risk)
References
Guidelines and key sources
DHHS Adult OI Guidelines 2025
Benson C, Brooks J, Dhanireddy S, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. IDSA/OARAC. 2025
Available at: clinicalinfo.hiv.gov
Primary source for TMP-SMX dosing, prophylaxis thresholds, and corticosteroid indications
DHHS Pediatric OI Guidelines 2025
Kapogiannis BG, Yates F, Li W, et al. Guidelines for Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV. OARAC. 2025
Prophylaxis thresholds and pediatric dosing protocols
American Society of Transplantation Infectious Diseases Practice Guidelines
Fishman JA, Gans H, AST IDCP. Pneumocystis jiroveci in solid organ transplantation. Clin Transplant. 2019
Post-transplant prophylaxis duration and risk stratification
Landmark studies and systematic reviews
Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487-2498
Foundational review: pathophysiology, epidemiology, diagnosis, and treatment
Stern A, Green H, Paul M, et al. Prophylaxis for Pneumocystis pneumonia in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014
Evidence base for prophylaxis in non-HIV populations
Fishman JA. Pneumocystis jiroveci. Semin Respir Crit Care Med. 2020
Non-HIV PCP: distinct pathophysiology and higher mortality
Giacobbe DR, Dettori S, Di Pilato V, et al. Pneumocystis jirovecii pneumonia in intensive care units. Crit Care. 2023
ICU mortality data: 52% at 30 days, 67% at 90 days
Prosty C, Luo OD, Khalaf R, et al. Diagnostic test accuracy of the Fungitell beta-D-glucan assay for PCP. Clin Microbiol Infect. 2025
Meta-analysis of BDG sensitivity (~83%) and NPV for PCP diagnosis
Nagai T, Matsui H, Fujioka H, et al. Low-dose vs conventional-dose TMP-SMX for PCP in non-HIV patients. Chest. 2023
Retrospective data on lower-dose TMP-SMX in non-HIV PCP
Falco-Roget A, Albasanz-Puig A, Perez-Gonzalez A, et al. Combined serum BDG and oral wash PCR for PCP diagnosis. Open Forum Infect Dis. 2026
Non-invasive diagnostic strategy: accuracy 97.9% in non-HIV patients
Pulsipher AM, Vikram HR, Gotway MB, et al. Observational analysis of a large PCP cohort. Open Forum Infect Dis. 2025
Modern epidemiology: non-HIV cohort distribution and prophylaxis rates
NCCN Guidelines: Prevention and Treatment of Cancer-Related Infections. Updated 2026
Prophylaxis indications and thresholds in oncology patients
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.